Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China

Arch Gynecol Obstet. 2021 Aug;304(2):567-569. doi: 10.1007/s00404-020-05829-3. Epub 2021 Jan 2.

Tianli Chang^#¹, Su Song^#², Donghui Huang^{1

2}, Ping Su^{1

2}, Xianjin Xiao^{1

2}, Honggang Li^{1

2}, Aihua Liao^{1

2}, Wenpei Xiang^{3

4

5}

¹ Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³ Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [email protected].
⁴ Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [email protected].
⁵ Institute of Reproductive Health, Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [email protected].

^# Contributed equally.

No abstract available

Keywords: COVID-19; Lymphocyte immunotherapy; Recurrent miscarriage; SARS-CoV-2.

Publication types